Nitric oxide synthase inhibition lowers activity of neurons with meningeal input in the rat spinal trigeminal nucleus

NeuroReport

Volumn 14, Issue 2, 2003, Pages 229-232

  De Col, Roberto ^a   Koulchitsky, Stanislav V ^a   Messlinger, Karl B ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Dura mater encephali; Electrophysiology; Headache; L NAME; Nitric oxide; Spinal trigeminal nucleus

Indexed keywords

N(G) NITRO DEXTRO ARGININE METHYL ESTER; N(G) NITROARGININE METHYL ESTER; NEUROTRANSMITTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; BIOSYNTHESIS; BRAIN ELECTROPHYSIOLOGY; BRAIN FUNCTION; CELL ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; DURA MATER; ENZYME INHIBITION; HEADACHE; MALE; MIGRAINE; NERVE CELL; NERVE CELL STIMULATION; NERVE EXCITABILITY; NEUROTRANSMITTER RELEASE; NOCICEPTIVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; SENSORY NERVE CONDUCTION; SPINAL CORD DORSAL HORN; TRIGEMINAL NUCLEUS;

ACTION POTENTIALS; ANIMALS; ENZYME INHIBITORS; MALE; MENINGES; NEURONS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; TRIGEMINAL NUCLEUS, SPINAL;

EID: 0037428759     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200302100-00014     Document Type: Article

References (23)

1. Ray BS and Wolff HG. Arch Surg 1, 813-856 (1940).
2. Boissonade FM, Sharkey KA and Lucier GE. J Comp Neurol 329, 291-312 (1993).
3. Bae YC, Ihn HJ, Park MJ et al. J Comp Neurol 418, 299-309 (2000).
4. Meller ST and Gebhart GF. Pain 52, 127-136 (1993).
5. Ohkuma S and Katsura M. Prog Neurobiol 64, 97-108 (2001).
6. Olesen J, Thomsen LL, Lassen LH et al. Cephalalgia 15, 94-100 (1995).
7. Thomsen LL, Kruuse C, Iversen H et al. Eur J Neurol 1, 73-80 (1994).
8. Lassen LH, Ashina M, Christiansen I et al. Lancet 349, 401-402 (1997).
9. Zimmermann M. Pain 16, 109-110 (1983).
10. Ellrich J, Schepelmann K, Pawlak M et al. Pain 81, 7-14 (1999).
11. Schepelmann K, Ebersberger A, Pawlak M et al. Neuroscience 90, 543-554 (1999).
12. Forster C and Handwerker HO. J Neurosci Methods 31, 109-118 (1990).
13. Yamamura H, Malick A, Chamberlin NL et al. J Neurophysiol 81, 479-493 (1999).
14. Handy RL and Moore PK. Br J Pharmacol 123, 1119-1126 (1998).
15. Goadsby PJ, Uddman R and Edvinsson L. Brain Res 707, 110-118 (1996).
16. Roth J, Storr B, Voigt K et al. Pflugers Arch 436, 858-862.
17. Umans JG and Levi R. Annu Rev Physiol 57, 771-790 (1995).
18. Ortega MA and De Artinano AA. Pharmacol Res 42, 421-427 (2000).
19. Garry MG, Richardson JD and Hargreaves KM. J Neurosci 14, 4329-4337 (1994).
20. Tassorelli C, Joseph SA and Nappi G. Neuropharmacology 36, 1417-1424 (1997).
21. Dohrn CS and Beitz AJ. Neurosci Lett 175, 28-32 (1994).
22. Ashina M, Bendtsen L, Jensen R et al. Brain 123, 1830-1837 (2000).
23. Ashina M, Lassen LH, Bendtsen L et al. Lancet 353, 287-289 (1999).